AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34533034 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental strategy: 75 to 100 mg aspirin daily plus 90 mg ticagrelor twice daily for 1 month, followed by 23 months of ticagrelor monotherapy
Number of subjects: 15000
Study 34533034 — intervention group
Group type: COMPARATOR
Intervention: Reference strategy: 75 to 100 mg aspirin daily plus either 75 mg clopidogrel daily (for SCAD) or 90 mg ticagrelor twice daily (for ACS) for 12 months, followed by aspirin monotherapy for 12 months
Number of subjects: 15000
Study 34533034 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental strategy
Number of subjects: 15000
Study 34533034 — intervention group
Group type: COMPARATOR
Intervention: Reference strategy
Number of subjects: 15000
Study 32513294 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg daily for 3 days, then tapered down over 6 weeks)
Number of subjects: 90
Study 32513294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 32513294 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 90
Study 33686445 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dermatologists
Number of subjects: 200
Study 33686445 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatologists
Number of subjects: 200
Study 35348606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Number of subjects: 74
Study 35348606 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 74
Study 33809168 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF testing in 2018 and 2019
Number of subjects: 1940
Study 33809168 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF testing in Bukhara region
Number of subjects: 1940
Study 33809168 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration from initial visit to receiving results in Tashkent city
Number of subjects: 1940
Study 33809168 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration from initial visit to receiving results in Bukhara region
Number of subjects: 1940
Study 32639465 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (once-daily, age-adjusted doses)
Number of subjects: 146
Study 32639465 — intervention group
Group type: COMPARATOR
Intervention: Comparator (vancomycin, nafcillin or equivalent)
Number of subjects: 146
Study 32639465 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 146
Study 32639465 — intervention group
Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 146
Study 34458925 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% acetaminophen gel
Number of subjects: 17
Study 34458925 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% acetaminophen gel
Number of subjects: 17
Study 34458925 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% acetaminophen gel
Number of subjects: 17
Study 34458925 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 17
Study 34455556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg as needed (PRN) for patients with 2-8 MMD
Number of subjects: 1800
Study 34455556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg as needed (PRN) for patients with 9-14 MMD
Number of subjects: 1800
Study 34455556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant on a fixed every-other-day schedule plus as needed dose (QOD+PRN) for patients with 4-14 MMD
Number of subjects: 1800
Study 32255205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided betamethasone injection with hydrodissection (5 mL)
Number of subjects: 20
Study 32255205 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided betamethasone injection without hydrodissection (2 mL)
Number of subjects: 20
Study 33812699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (arginine)/tramadol 400/37.5 mg
Number of subjects: 118
Study 33812699 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg alone
Number of subjects: 118
Study 33812699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen arginine 400 mg alone
Number of subjects: 118
Study 33812699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 33257486 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (rt-CGM)
Number of subjects: 372
Study 33257486 — intervention group
Group type: COMPARATOR
Intervention: Self-monitored blood glucose (SMBG)
Number of subjects: 372
Study 36243225 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockable rhythm
Number of subjects: 256
Study 36243225 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-shockable rhythm
Number of subjects: 256
Study 36243225 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment (n = 124) with shockable rhythm
Number of subjects: 256
Study 36243225 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment (n = 124) with non-shockable rhythm
Number of subjects: 256
Study 36243225 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment (n = 132) with shockable rhythm
Number of subjects: 256
Study 36243225 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment (n = 132) with non-shockable rhythm
Number of subjects: 256
Study 33929523 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR (Comprehensive Medication Review)
Number of subjects: 2637
Study 33929523 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR plus postdischarge follow-up
Number of subjects: 2637
Study 33929523 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2637
Study 34844995 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 30
Study 34844995 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy
Number of subjects: 30
Study 36198259 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 109
Study 36198259 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 109
Study 34127260 — intervention group
Group type: COMPARATOR
Intervention: Pair housing (C)
Number of subjects: 66
Study 34127260 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual housing (I)
Number of subjects: 66
Study 33242783 — intervention group
Group type: EXPERIMENTAL
Intervention: Good stroke knowledge for action (defined as recognition of impaired strength, sensation, and language plus intention to seek urgent medical attention in a hypothetical stroke situation)
Number of subjects: 1986
Study 33242783 — intervention group
Group type: EXPERIMENTAL
Intervention: Good stroke knowledge for action
Number of subjects: 1986
Study 32466773 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg magnesium oxide plus 150 mg zinc sulfate for 12 weeks
Number of subjects: 60
Study 32466773 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study 35623045 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial and social support systems, such as governmental and school resources
Number of subjects: 38
Study 35623045 — intervention group
Group type: EXPERIMENTAL
Intervention: Faculty members' flexibility and students' experience with online learning
Number of subjects: 38
Study 33536010 — intervention group
Group type: COMPARATOR
Intervention: Ozone (3 doses weekly)
Number of subjects: 238
Study 33536010 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA) (3 doses weekly)
Number of subjects: 238
Study 33536010 — intervention group
Group type: COMPARATOR
Intervention: Platelet Rich Plasma (PRP) (2 doses with 3 weeks interval)
Number of subjects: 238
Study 33536010 — intervention group
Group type: COMPARATOR
Intervention: Plasma Rich in Growth Factors (PRGF) (2 doses with 3 weeks interval)
Number of subjects: 238
Study 32216964 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled low central venous pressure
Number of subjects: 146
Study 32216964 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 146
Study 35133411 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 8144
Study 35133411 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 8144
Study 35133411 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 8144
Study 35133411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8144
Study 35133411 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of medication and behavioral counseling
Number of subjects: 8144
Study 34074584 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg−1.kg−1 body mass)
Number of subjects: 10
Study 32011156 — intervention group
Group type: EXPERIMENTAL
Intervention: Language learning (Italian) for 11 weeks
Number of subjects: 160
Study 32011156 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training for 11 weeks
Number of subjects: 160
Study 33712389 — intervention group
Group type: EXPERIMENTAL
Intervention: RARC with iUD
Number of subjects: 51
Study 33712389 — intervention group
Group type: COMPARATOR
Intervention: ORC
Number of subjects: 51
Study 33420720 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV-6 serology in patients with COVID-19 and cutaneous manifestations
Number of subjects: 12
Study 33420720 — intervention group
Group type: COMPARATOR
Intervention: HHV-6 serology in hospitalized patients with COVID-19 without cutaneous manifestations
Number of subjects: 12
Study 34275099 — intervention group
Group type: EXPERIMENTAL
Intervention: Incretin-based therapy (sitagliptin followed by liraglutide)
Number of subjects: 249
Study 34275099 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 249
Study 35794140 — intervention group
Group type: COMPARATOR
Intervention: VIBE-based single-artery phase imaging (Group A, n=50)
Number of subjects: 140
Study 35794140 — intervention group
Group type: COMPARATOR
Intervention: StarVIBE (Group B, n=44)
Number of subjects: 140
Study 35794140 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIPIRINHA-Dixon-TWIST-VIBE (CDT-VIBE)-based multi-artery phase imaging (Group C, n=46)
Number of subjects: 140
Study 34266320 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SLE
Number of subjects: 227
Study 34266320 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 227
Study 34472504 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterolane maleate (AM) 37.5 mg and piperaquine phosphate (PQP) 187.5 mg
Number of subjects: 164
Study 34472504 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine phosphate
Number of subjects: 164
Study 34656406 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (TM)
Number of subjects: 0
Study 34656406 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study 33144299 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 18
Study 33144299 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (SS)
Number of subjects: 18
Study 32887564 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - 4 sessions by trained nurses
Number of subjects: 272
Study 32887564 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 272
Study 32887564 — intervention group
Group type: COMPARATOR
Intervention: Standard geriatric rehabilitation alone
Number of subjects: 272
Study 33070154 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐42165279 (25 mg daily)
Number of subjects: 149
Study 33070154 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 149
Study 32657195 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked color imaging (LCI)
Number of subjects: 1278
Study 32657195 — intervention group
Group type: COMPARATOR
Intervention: HD white-light colonoscopy (WLC)
Number of subjects: 1278
Study 35752551 — intervention group
Group type: EXPERIMENTAL
Intervention: HA+C Group (Hyaluronic Acid plus Corticosteroid)
Number of subjects: 25
Study 35752551 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid Group (Isolated Corticosteroid)
Number of subjects: 25
Study 33372523 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting LA reservoir strain (LASr)
Number of subjects: 218
Study 33372523 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise E/e’
Number of subjects: 218
Study 33372523 — intervention group
Group type: EXPERIMENTAL
Intervention: Model combining LASr and clinical metrics
Number of subjects: 218
Study 33372523 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting echocardiographic parameters (E/e’, LASr, LA contractile strain)
Number of subjects: 218
Study 34420037 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide plus ADT (n=574)
Number of subjects: 1150
Study 34420037 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ADT (n=576)
Number of subjects: 1150
Study 35126199 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 52
Study 35126199 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity exercise
Number of subjects: 52
Study 33162202 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pentavalent rotavirus vaccine
Number of subjects: 0
Study 33162202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33162202 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antibodies
Number of subjects: 0
Study 33727659 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bromfenac sodium ophthalmic solution
Number of subjects: 26
Study 33727659 — intervention group
Group type: COMPARATOR
Intervention: 0.02% fluorometholone ophthalmic suspension
Number of subjects: 26
Study 36279020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 50
Study 36279020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 33532885 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin-α late-start (day 4)
Number of subjects: 0
Study 33532885 — intervention group
Group type: COMPARATOR
Intervention: Standard administration (day 2)
Number of subjects: 0
Study 32419549 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher graft CD34+ cell content (>2.5 × 10^6/kg)
Number of subjects: 129
Study 32419549 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher graft CD34+CD133+CD38– counts (>0.08 × 10^6/kg)
Number of subjects: 129
Study 32419549 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher infused CD3+CD4+ cell count (>37 × 10^6/kg)
Number of subjects: 129
Study 34713371 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted surgery
Number of subjects: 468
Study 34713371 — intervention group
Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 468
Study 34713371 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 468
Study 34252034 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Operating Room Tour (VORT)
Number of subjects: 84
Study 34252034 — intervention group
Group type: COMPARATOR
Intervention: Standard operation preparation procedure
Number of subjects: 84
Study 35956425 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic, Web-Based, Weight Loss Intervention
Number of subjects: 0
Study 35956425 — intervention group
Group type: COMPARATOR
Intervention: Control group measures
Number of subjects: 0
Study 33710344 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-polyphenol (PP) drinks
Number of subjects: 18
Study 33710344 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric maltodextrin placebo (PLA) drinks
Number of subjects: 18
Study 36070825 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel 3D-printed custom tray
Number of subjects: 15
Study 36070825 — intervention group
Group type: COMPARATOR
Intervention: Conventional impression tray
Number of subjects: 15
Study 36070825 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic denture impression
Number of subjects: 15
Study 36070825 — intervention group
Group type: COMPARATOR
Intervention: Conventional impression
Number of subjects: 15
Study 32606097 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (paclitaxel weekly or pegylated liposomal doxorubicin) + bevacizumab + atezolizumab
Number of subjects: 664
Study 32606097 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (paclitaxel weekly or pegylated liposomal doxorubicin) + bevacizumab + placebo
Number of subjects: 664
Study 33802559 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive dynamic balance training (PDBT) with physical therapy
Number of subjects: 38
Study 33802559 — intervention group
Group type: COMPARATOR
Intervention: Control group (physical therapy only)
Number of subjects: 38
Study 32976938 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg/Q3W)
Number of subjects: 144
Study 32976938 — intervention group
Group type: COMPARATOR
Intervention: Single-agent chemotherapy (gemcitabine or vinorelbine)
Number of subjects: 144
Study 33681651 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 1121
Study 32521745 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Resistance Training (HIIRT)
Number of subjects: 20
Study 32521745 — intervention group
Group type: COMPARATOR
Intervention: Traditional Resistance Training (TRT)
Number of subjects: 20
Study 33319755 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pregnancy treatment (nutrition counseling, glucose monitoring, medications as needed)
Number of subjects: 157
Study 35712968 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC (n=92)
Number of subjects: 184
Study 35712968 — intervention group
Group type: COMPARATOR
Intervention: Control (n=92)
Number of subjects: 184
Study 32390123 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated sunlight (1.3× standard-erythema dose, 3×/week for 4 weeks and then 1×/week for 8 weeks)
Number of subjects: 119
Study 32390123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (1000 IU/day for 4 weeks and 400 IU/day for 8 weeks)
Number of subjects: 119
Study 32390123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 32390123 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin D status (25(OH)D ≤ 40 vs 41-71 nmol/L)
Number of subjects: 119
Study 32390123 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin D status (1,25(OH)2D ≤ 120 vs ≥ 157 pmol/L)
Number of subjects: 119
Study 32390123 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter vaccination vs summer vaccination
Number of subjects: 119
Study 36428098 — intervention group
Group type: EXPERIMENTAL
Intervention: UC+MI
Number of subjects: 514
Study 36428098 — intervention group
Group type: EXPERIMENTAL
Intervention: UC+SVAI
Number of subjects: 514
Study 36428098 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 514
Study 34036321 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour urinary sucrose and fructose (24uSF) biomarker
Number of subjects: 98
Study 34036321 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration of the biomarker
Number of subjects: 98
Study 34036321 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibrated biomarker based on a single measurement
Number of subjects: 98
Study 34036321 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibrated biomarker based on 4 repeats
Number of subjects: 98
Study 33067279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane treatment for 12 weeks
Number of subjects: 90
Study 33067279 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 90
Study 33067279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane treatment
Number of subjects: 90
Study 35192016 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% Hypertonic Saline (3% HTS)
Number of subjects: 93
Study 35192016 — intervention group
Group type: COMPARATOR
Intervention: 0.9% Saline (NS)
Number of subjects: 93
Study 33006504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanolic extract of Opuntia ficus-indica var. saboten (OFE) administered for 12 weeks
Number of subjects: 81
Study 33006504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 35617960 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational video
Number of subjects: 82
Study 35617960 — intervention group
Group type: COMPARATOR
Intervention: Standard informed consent process
Number of subjects: 82
Study 33487626 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory workplace improvement program
Number of subjects: 31
Study 32737350 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with LCPUFA (docosahexaenoic acid 300 mg/day, eicosapentaenoic acid 100 mg/day, arachidonic acid 120 mg/day)
Number of subjects: 76
Study 32737350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 32737350 — intervention group
Group type: COMPARATOR
Intervention: No exercise with placebo
Number of subjects: 76
Study 34776140 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) exercise program
Number of subjects: 26
Study 34776140 — intervention group
Group type: COMPARATOR
Intervention: Non-BFR control group (CG)
Number of subjects: 26
Study 36202586 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein concentrate (MPC) supplementation
Number of subjects: 44
Study 36202586 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study 33415379 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) injection (1-mL)
Number of subjects: 2
Study 33415379 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TA) injection (0.5-mL)
Number of subjects: 2
Study 32899673 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) supplementation (FO and FO + 5-MTHF groups, n = 33)
Number of subjects: 57
Study 32899673 — intervention group
Group type: COMPARATOR
Intervention: No Fish Oil (No-FO group, placebo and 5-MTHF groups, n = 24)
Number of subjects: 57
Study 33883048 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk oral care
Number of subjects: 56
Study 33883048 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline oral care
Number of subjects: 56
Study 32903275 — intervention group
Group type: EXPERIMENTAL
Intervention: K3XF
Number of subjects: 180
Study 32903275 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Next
Number of subjects: 180